Human Coagulation FACTOR X ( DrugBank: Coagulation factor X, Factor X, Human coagulation factor X )


1 disease
IDDisease name (Link within this page)Number of trials
288Autoimmune acquired coagulation factor deficiency3

288. Autoimmune acquired coagulation factor deficiency


Clinical trials : 205 Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-003093-98-GB
(EUCTR)
24/02/201502/01/2013The purpose of this study is to look at how well FACTOR X works in preventing bleeding when taken regularly in children aged under 12 years old, over a period of 6 months. The study will also look at how safe FACTOR X is by closely following the subjects progress during the study.A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Product Name: Human factor X
Product Code: FACTOR X
INN or Proposed INN: Human Coagulation Factor X
Other descriptive name: FACTOR X
Bio Products Laboratory LimitedNULLNot RecruitingFemale: yes
Male: yes
8Phase 3Turkey;United Kingdom
2NCT00930176
(ClinicalTrials.gov)
January 201010/6/2009A Study Investigating Treatment Factor X in People With Factor X DeficiencyA Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.Factor X DeficiencyBiological: Human Coagulation FACTOR XBio Products LaboratoryNULLCompleted12 YearsN/AAll16Phase 3United States;Germany;Spain;Turkey;United Kingdom
3EUCTR2009-011145-18-GB
(EUCTR)
02/11/200924/09/2009A study for people with severe and moderate coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate, and how it is handled by the body.A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiency Factor X deficiency
MedDRA version: 14.1;Level: PT;Classification code 10052474;Term: Factor X deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Human factor X
Product Code: FACTOR X
INN or Proposed INN: Human coagulation Factor X
Other descriptive name: Human factor X
Bio Products Laboratory LtdNULLNot RecruitingFemale: yes
Male: yes
16Phase 3United States;Spain;Turkey;Germany;United Kingdom